Today, MyRNA Diagnostics is proud to participate in the Next Generation Genomics (NGG) Conference 2026, joining key stakeholders across Malaysia’s cli...
Today, MyRNA Diagnostics is proud to participate in the Next Generation Genomics (NGG) Conference 2026, joining key stakeholders across Malaysia’s clinical, research, and policy ecosystem to advance the future of precision diagnostics.
As Malaysia continues to face a rising cancer burden—with over 60% of cancers detected at late stages—the need for accessible, early detection solutions has never been more critical. At MyRNA, we are committed to addressing this gap through our microRNA-powered platforms:
GastroClear – enabling early detection of gastric cancer with high clinical accuracy
LungClear – a non-invasive blood-based test supporting early lung cancer risk stratification
Our participation reflects a broader mission:
➡️ Strengthening Malaysia’s shift from curative to preventive care
➡️ Enabling “blood-first triage” in cancer screening pathways
➡️ Positioning Malaysia as a regional hub for molecular diagnostics innovation
We look forward to continued collaboration with clinicians, researchers, and policymakers to accelerate early detection, better outcomes, and sustainable healthcare impact.
MyRNA Diagnostics
Precision Diagnostics, Made Just in Time
#MyRNA #NGG2026 #PrecisionDiagnostics #EarlyCancerDetection #Genomics #MOHMalaysia